LIPO — Lipella Pharmaceuticals Cashflow Statement
0.000.00%
- $3.48m
- $1.37m
- $0.45m
- 32
- 18
- 19
- 12
Annual cashflow statement for Lipella Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.062 | -0.062 | -1.87 | -2.6 | -4.62 |
Depreciation | |||||
Non-Cash Items | 0.008 | 0.065 | 0.679 | 0.757 | 1.48 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.014 | -0.032 | 0.198 | 0.01 | -0.009 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -0.039 | -0.029 | -0.989 | -1.83 | -3.15 |
Capital Expenditures | — | — | — | — | -0.014 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | 0 | -0.301 | 0.301 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | — | 0 | -0.301 | 0.301 | -0.014 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.025 | 0.609 | 2.1 | 5.24 | 1.34 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.014 | 0.581 | 0.807 | 3.71 | -1.83 |